UnitedHealth CEO says no copay for insulin, other critical drugs from 2023
9:16 AM EDT
July 15 (Reuters) – UnitedHealth Inc (UNH.N) Chief Executive Officer Andrew Witty said on Friday that beginning next year there would be no copay or out-of-pocket costs for several critical medicines, including insulin, for fully insured members.
The news comes amid heightened public scrutiny over soaring prices of the life-saving drug, with the U.S. House of Representatives in March passing a bill that caps monthly out-of-pocket insulin costs at $35 for those with health insurance.
Other medicines in the list include epinephrine for severe allergic reactions and albuterol for acute asthma attacks, Witty said.
Our Standards: The Thomson Reuters Trust Principles.